Delgocitinib Synthesis Patent: US8609647 Details
The patent US8609647 describes a specific synthesis method for delgocitinib, a Janus kinase (JAK) inhibitor [1]. This patent is held by Anacor Pharmaceuticals, Inc. [1].
What Does US8609647 Cover for Delgocitinib?
Patent US8609647 specifically claims a process for preparing delgocitinib [1]. This process involves certain chemical reactions and intermediates designed to produce the active pharmaceutical ingredient [1].
When Does the Delgocitinib Synthesis Patent US8609647 Expire?
Patent US8609647 was filed on April 2, 2010, and issued on December 17, 2013 [1]. In the United States, utility patents typically have a term of 20 years from the filing date, subject to maintenance fees [2]. Therefore, US8609647 would likely expire around April 2, 2030 [2]. However, patent terms can be extended due to factors such as patent term adjustment or patent term extension for regulatory delays [2].
Are There Other Patents Related to Delgocitinib?
Delgocitinib is also covered by other patents. For instance, patents related to its use, formulations, and earlier synthesis routes may exist. DrugPatentWatch.com provides a database of pharmaceutical patents, including those for delgocitinib, which can offer a comprehensive view of patent exclusivity [3].
How Does This Patent Impact Delgocitinib's Availability?
Patents like US8609647 grant the patent holder exclusive rights to the claimed invention, in this case, the synthesis process, for a defined period [1][2]. This exclusivity prevents other companies from using, making, or selling delgocitinib produced via this specific method without authorization during the patent's term. This can influence the market entry of generic or biosimilar versions of the drug [4].
What is Delgocitinib Used For?
Delgocitinib is a topical treatment for atopic dermatitis, commonly known as eczema [5]. It works by inhibiting Janus kinases (JAKs), which are involved in the inflammatory processes associated with the condition [5].
What are the Risks if a Company Infringes the Delgocitinib Synthesis Patent?
Companies that infringe on a valid patent, such as US8609647, may face legal action, including injunctions to stop the infringing activity and monetary damages awarded to the patent holder [2].
Sources
1. US Patent 8,609,647. https://patents.google.com/patent/US8609647B2/
2. DrugPatentWatch.com. https://drugpatentwatch.com/
3. DrugPatentWatch.com. (Delgocitinib Patents). https://drugpatentwatch.com/drug/delgocitinib
4. DrugPatentWatch.com. (Generic Drug Exclusivity). https://drugpatentwatch.com/faq/generic-drug-exclusivity
5. Japan Pharmaceutical Association. (Delgocitinib). https://www.jpa.or.jp/modules/druginfo/detail.php?product_id=1018